![Complement Activation In Rheumatoid Arthritis Complement Activation In Rheumatoid Arthritis](http://www.download.thelancet.com/cms/attachment/2001011624/2003799208/gr1.jpg)
RA Pathophysiology. Rheumatoid arthritis is characterized by the presence of autoantibodies known as rheumatoid factors (RF). leukotriene B4, and possibly localized complement activation through C5a.
Rheumatoid arthritis and the complement system. Pub. Med. Abstract. Complement activation contributes to a pathological process in a number of autoimmune and inflammatory diseases, including rheumatoid arthritis (RA).
Arthritis & Rheumatism > Vol 44 Issue 5 > Abstract; JOURNAL TOOLS. Get New Content Alerts. Complement activation contributes to a pathological process in a number of autoimmune and inflammatory diseases, including rheumatoid arthritis (RA).
Complement in the immunopathogenesis of rheumatic disease. is associated with autoantibodies and complement activation. Arthritis Rheum. 64. Rheumatoid arthritis and the complement system.
Evaluation of classical complement pathway activation in rheumatoid arthritis. 2006), Evaluation of classical complement pathway activation in rheumatoid. complement activation may explain at least part. Molenaar ET(1), Voskuyl AE, Familian A, van Mierlo GJ, Dijkmans BA, Hack CE. Author information: (1)Vrije Universiteit Medical Center, Amsterdam, The Netherlands. Comment in Arthritis Rheum. 2001 May;44(5):995-6. OBJECTIVE. The complement system is an essential component of innate immunity and also plays an important role in. Complement activation in rheumatoid arthritis evaluated by C3dg and the terminal complement complex.. Complement activation contributes to a pathological process in a number of autoimmune and inflammatory diseases, including rheumatoid arthritis (RA). In this review we summarize current knowledge of complement contribution to.
In this review we summarize current knowledge of complement contribution to RA, based on clinical observations in patients and in vivo animal models, as well as on experiments in vitro aiming at elucidation of underlying molecular mechanisms. There is strong evidence that both the classical and the alternative pathways of complement are pathologically activated during RA as well as in animal models for RA. The classical pathway can be initiated by several triggers present in the inflamed joint such as deposited autoantibodies, dying cells, and exposed cartilage proteins such as fibromodulin. B cells producing autoantibodies, which in turn form immune complexes, contribute to RA pathogenesis partly via activation of complement. It appears that anaphylatoxin C5a is the main product of complement activation responsible for tissue damage in RA although deposition of membrane attack complex as well as opsonization with fragments of C3b are also important.
Success of complement inhibition in the experimental models described so far encourages novel therapeutic approaches to the treatment of human RA.
![Complement Activation In Rheumatoid Arthritis Complement Activation In Rheumatoid Arthritis](http://www.sec.gov/Archives/edgar/data/875045/000095013508001206/b68851dab68851bz0013.gif)
![Complement Activation In Rheumatoid Arthritis Complement Activation In Rheumatoid Arthritis](http://www.intechopen.com/source/html/41756/media/image3.png)
Okroj M(1), Heinegård D, Holmdahl R, Blom AM. Author information: (1)Lund University, Department of Laboratory Medicine, University Hospital Malmö, Malmö, Sweden. Complement activation contributes to a pathological process. Abstract. Objective. Complement activation has been shown to occur in patients with juvenile rheumatoid arthritis (JRA). Since the two pathways of complement are activated by different stimuli (the alternate.
Evidence for activation of the alternate complement pathway in patients with juvenile rheumatoid arthritis. A. Aggarwal. 1. A. Bhardwaj. S. Alam and. R. Misra. Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 2.
India. Received August 1. Revision received June 2. Abstract. Objective. Complement activation has been shown to occur in patients with juvenile rheumatoid arthritis (JRA). Since the two pathways. Ig. A, and the classical pathway.
JRA. Methods. In 5. JRA, plasma levels of C3 and C4 were measured by turbidimetric assays, and those of C4d, factor Bb and. C5‐9 complex by solid‐phase enzyme immunoassays. Levels beyond the mean ± 2 s. Results. Plasma C3 and C4 levels were decreased in one patient each. The C4d values were increased in 1.
Bb were elevated in 4. C5‐9 complex were elevated in 5. The values of factor Bb. C5‐9 had a linear correlation (r = 0. C4d and s. C5‐9 levels (r = 0. Conclusion. Complement activation in JRA is initiated predominantly by the alternate pathway and culminates in the formation of terminal.
Juvenile rheumatoid arthritis (JRA) is a chronic systemic inflammatory disease of childhood. It is classified into three subtypes. Even though immune complexes have been found in blood and synovial fluid in all forms of JRA, the role of complement activation. Studies on complement pathway activation in patients with JRA have shown conflicting results.
Initial studies showed that. C3 and C4 were normal in patients with JRA. Later, measurement of complement activation products C3c, C3dg and C4a in plasma and synovial fluid of patients with JRA.
Miller et al.[1] found levels of serum complement degradation products C3d and C3a to be elevated in the systemic and polyarticular type of. Another study [5] reported that both classical and alternative complement activation fragments are elevated in children with polyarticular.
Both these pathways converge to a common pathway which leads to the generation of membrane terminal attack. TAC). The TAC exists in two forms: the membrane‐bound form which can be found on cells and tissues, and the fluid. C5‐9 complex which can be detected in body fluids. Changes in the TAC have been studied in only a few patients with. JRA [4]. The classical and alternate pathways are activated by different stimuli, and studying their relative contribution to complement. Also, since the tissue damage is mediated by TAC, it may be.
We therefore studied the levels of TAC, C4d and factor Bb in patients. JRA to determine the relative contribution of the classical and alternate pathways in the generation of TAC. Patients and methods.
Fifty‐six patients with JRA satisfying the American College of Rheumatology (ACR) criteria [7], and seen at our clinic between April 1. October 1. 99. 7, were enrolled in the study. Data regarding the type of disease. In addition, current.
The erythrocyte sedimentation rate (ESR) and concentration of haemoglobin and C‐reactive protein. CRP) were measured as laboratory parameters of disease activity. Active disease was defined as the presence of systemic manifestations. CRP (> 1. 2 mg/dl) or ESR (> 2. All patients were carefully screened for any infection in the preceding 4 weeks and, if there was any doubt.
In three patients three samples each, and in seven patients two samples each, were. Plasma samples from 1.
For complement studies, blood was collected in EDTA and transported on ice to the laboratory. Plasma was separated and then.
C until analysis. Levels of C3 and C4 were measured by a turbidimetric method using anti‐C3c and anti‐C4 antibodies. Behring, Germany).
Concentrations of complement degradation products (C4d, factor Bb and s. C5‐9 complex) were measured by. EIA) (Quidel Corporation, San Diego, CA, USA). The C4d level was used as a measure of activation of the classical pathway, whereas factor Bb levels reflected activation. The s. C5‐9 levels are a measure of the amount of the TAC generated as a result of activation of the. In brief, test plasma specimens in appropriate dilution were added to EIA wells coated with monoclonal antibody to the respective.
After washing, a second antibody conjugated with horseradish peroxidase was added. This was followed by the addition of tetra methyl benzadine (TMB) substrate; the reaction was stopped after 1. For each analyte, concentrations in the test samples were read from a standard plot between absorbance.
Values above the mean ± 2 s. Statistical analysis.
Pearson's correlation coefficient was used to study the relationship of various continuous variables with one another. Kruskal–Wallis. one‐way ANOVA was used for detecting differences between different subtypes. An alpha error of < 0. Results. The mean age of patients was 1. Of the 5. 6 patients studied, 2. The disease was active in 5. Fifty‐four patients were receiving non‐steroidal anti‐inflammatory.
Of the 5. 6 patients, C3 and C4 levels were decreased in one patient each. The levels of the complement degradation products.
C4d, factor Bb and s. C5‐9 complex, were higher in patients as compared with controls (P < 0. The C4d levels were increased in only 1. Bb were elevated in 4. C5‐9 complex were increased in 5.
There was a trend towards higher levels of C4d, Bb and s. C5‐9 in polyarticular.
JRA, but it was not statistically significant, probably due to the small number of patients. Table 1⇔). Among the patients with elevated s. C5‐9, only three had elevated C4d alone, 2. Bb alone, whereas in. C4d and factor Bb were elevated.
In six patients with elevated s. C5‐9, both C4d and factor Bb were normal. The value. of Bb and s.
C5‐9 had a linear correlation (r = 0. P < 0. 0. 1) (Fig. 1⇔), while there was no significant correlation between C4d and s. C5‐9 levels (r = 0. P > 0. 0. 5). In addition, there was no significant correlation (r = 0. C4d and factor Bb. In 1. 0 patients, for whom two or three serial samples were tested, there was a direct relationship between the levels of factor. Bb and s. C5‐9; a rise in one was associated with a rise in the other (Fig. 2⇔), whereas the levels of C4d had no such relationship with s.
C5‐9 levels. Fig. 1. Scatterplot for plasma Bb and plasma s. C5‐9 complex. The Pearson's correlation coefficient is 0. P < 0. 0. 01). Fig. 2. Line diagram showing serial values of plasma Bb and plasma s. C5‐9 complex in three patients.
The solid line represents factor. Bb levels (μg/ml), while the dashed line (‐‐‐) represents s. C5‐9 complex levels (μg/ml). On the x‐axis, the time in months represents time since inclusion in the study. Table 1. Median [range] levels of complement components in patients with different types of JRADiscussion. Our data show that s.
C5‐9 levels are elevated in a majority of patients with JRA. This indicates that the complement pathway. TAC. Activation of the complement pathway has previously. TAC has been rarely reported.
Our data may thus provide more conclusive evidence for. JRA. The exact site of membrane TAC generation is not known. Complement activation can occur by the classical or the alternate pathway, or by a combination of the two. Our data suggest. JRA, with a minor contribution by the classical pathway. Activation of the classical pathway has been reported to occur in polyarticular, systemic‐onset disease [1, 5] and pauciarticular‐onset disease [3, 5]. Higher levels of C4d in systemic‐onset disease could suggest that in this variant more Ig.
G‐ and Ig. M‐containing immune complexes. Activation of the alternate pathway found by us was also present in the study reported by Jarvis et al.[5], but in that study patients with systemic‐onset disease were not included. Thus, our study is the first report of alternate. The presence of alternate pathway activation in three‐quarters of patients suggests.
In a recent study [6], levels of factor Bb were found to correlate better with the level of circulating immune complexes than levels of C4d, implying. Alternate pathway activation can occur by immune complexes bearing Ig. A rheumatoid factor (RF). Indeed, high‐molecular‐weight. Ig. A RF‐containing immune complexes have been described in children with polyarticular disease [8]. The alternate pathway is also the major mechanism of solubilization of large preformed aggregates [9], and there may be some immune complexes preformed in the tissues in patients with JRA which can activate the alternate pathway.
In addition, bacterial products can activate the alternate pathway. Analysis of immune complexes. JRA have revealed novel 4. Da bands which are resistant to DNase, RNase and proteases, suggesting. In contrast, in 1. Olds and Miller [3] failed to show the presence of antibodies to streptococcal cell wall peptidoglycan–polysaccharide polymers in the immune. JRA, indirectly showing that these antigens are not present in immune complexes of patients.
JRA. Rarely, a low level of C3b generated from activation of the classical pathway can perpetuate activation of the alternate. In addition, there may be some inhibitors of classical pathway activation like Ig. M RF, which is found in JRA and may inhibit.
C4b to Ig. G in the immune complexes and thus prevent the classical pathway activation [1. Thus, complement activation occurs in the majority and these complement degradation products, by inducing inflammation [1.
Since JRA is a heterogeneous disease and the different subtypes may have a different pathogenesis. In addition, analysis.
JRA for the presence of Ig. A RF, and the putative microbial products, may help.
Acknowledgments. This work was supported by an intramural research grant from the Sanjay Gandhi Postgraduate Institute of Medical Sciences. AA. Footnotes↵1 Correspondence to: A. Aggarwal, Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences. Lucknow 2. 26 0. 14, India. British Society for Rheumatology. References↵Miller JJ III, Olds LC, Silverman ED et al.
Different patterns of C3 and C4 activation in varied types of juvenile arthritis. Pediatr Res. 19. 86; 2. Miller JJ, Hsu Y‐P, Moss R, Kelomaa‐Sulonen K, Osborn CL, Olds‐Arroyo L.